“A good day for Martin Shkreli,” who may try to pin fraud on former counsel

Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, exits federal court in New York, US, on Thursday, December 17, 2015. Shkreli was arrested on alleged securities fraud related to Retrophin Inc., a biotech firm he founded in 2011. (credit: Louis Lanzano/Bloomberg via Getty Images)

In a Tuesday court hearing, a federal judge delayed setting a trial date for Martin Shkreli, the disgraced founder and ex-CEO of Turing Pharmaceuticals who was indicted on seven counts of securities fraud charges last December.

Shkreli and his lawyer requested the delay after learning recently that prosecutors are considering filing more charges against the embattled former executive and his ex counsel, Evan Greebel, who was already charged with one count of wire-fraud conspiracy. The new potential charges—along with the initial ones—relate to allegations that the pair ran a Ponzi-like scheme, in which they funneled millions of dollars out of Retrophin, another of Shkreli’s pharmaceutical companies, to cover losses from two hedge funds Shkreli managed.

In the Brooklyn federal court Tuesday, prosecutors told the judge that they would decide if they would file new charges within the month.